Internal Medicine, Hematology & Oncology · Cambridge, MA
NPI
1255363545
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1493 Cambridge St
Cambridge, MA, 02139
Phone (617) 665-1552
Groups this clinician bills Medicare through
Medicare paid, 2024
$27K
380 services
Medicare patients, 2024
171
Average age 74
Drug cost, 2024
$3.8M
862 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Debashish Misra was code 99214 (office e&m - established), 235 times for 98 patients. In total Debashish Misra billed 380 services in 15 codes, and Medicare paid $27K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-11-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 235 | 98 | $74.78 | $18K |
| 99213 Office E&M - Established | Facility | 53 | 46 | $41.57 | $2,203 |
| 99215 Office E&M - Established | Facility | 23 | 18 | $118.85 | $2,734 |
| 99203 Office E&M - New | Facility | 19 | 19 | $59.16 | $1,124 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 16 | 16 | $14.21 | $227 |
| 99204 Office E&M - New | Facility | 12 | 12 | $105.02 | $1,260 |
By year: 2022 $33K for 464 services; 2023 $31K for 424 services; 2024 $27K for 380 services.
Medicare prescription drug claims, 2024
In 2024, the drug Debashish Misra prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 70 prescriptions and refills. In total Debashish Misra wrote 862 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 70 | 70 | Under 11 | $932K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 49 | 49 | Under 11 | $487K |
| Lenalidomide Generic | 38 | 38 | Under 11 | $374K |
| Acyclovir Generic | 35 | 57 | Under 11 | $391 |
| Bortezomib Generic | 33 | 33 | Under 11 | $2,736 |
| Hydroxyurea Generic | 33 | 97 | Under 11 | $1,220 |
| Imatinib Mesylate Generic | 30 | 30 | Under 11 | $2,754 |
| Jevtana Cabazitaxel | 29 | 30 | Under 11 | $421K |
| Ondansetron Hcl Generic | 27 | 27 | 17 | $129 |
| Keytruda Pembrolizumab | 24 | 24 | Under 11 | $259K |
| Prednisone Generic | 24 | 41 | Under 11 | $162 |
| Lupron Depot Leuprolide Acetate | 23 | 90 | Under 11 | $132K |
| Eliquis Apixaban | 22 | 28 | Under 11 | $15K |
| Carboplatin Generic | 21 | 21 | Under 11 | $783 |
| Oxycodone Hcl Generic | 19 | 19 | Under 11 | $196 |
Brand drugs: 383 claims; generic drugs: 479 claims; opioid claims: 24.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Debashish Misra were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.